RGEN
Repligen Corporation · Healthcare · Medical - Instruments & Supplies
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +17.1% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 126 | +8 | 40.16M | $5.47B | +16 | −7 |
| Q1 2026 | 120 | -2 | 41.26M | $4.90B | +8 | −11 |
| Q4 2025 | 122 | -3 | 43.70M | $7.16B | +1 | −3 |
| Q3 2025 | 21 | +2 | 26.22M | $3.51B | +3 | −2 |
| Q2 2025 | 17 | +1 | 26.68M | $3.32B | +2 | −1 |
| Q1 2025 | 13 | +1 | 13.27M | $1.69B | +1 | — |
| Q4 2024 | 12 | 0 | 12.86M | $1.85B | +1 | −1 |
| Q3 2024 | 11 | -3 | 9.29M | $1.38B | — | −3 |
| Q2 2024 | 14 | — | 8.37M | $1.05B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 7.14M | +11.6% | $1.03B | 0.1% | ▲ Add | 3 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 7.14M | +11.6% | $1.03B | 0.1% | ▲ Add | 3 | SEC ↗ |
| 3 | State Street Global Advisors ✦ (passive) | 1.69M | — | $243.43M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 1.18M | +128.7% | $169.78M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 1.18M | +128.7% | $169.78M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 944.08K | +0.2% | $135.93M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 944.08K | +0.2% | $135.93M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 918.62K | +183.2% | $132.23M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 9 | Marshall Wace ✦ | 412.24K | +73.8% | $59.34M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 10 | Marshall Wace ✦ | 412.24K | +73.8% | $59.34M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 11 | Marshall Wace ✦ | 412.24K | +73.8% | $59.34M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 359.04K | -17.7% | $51.68M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 13 | Norges Bank ✦ (passive) | 166.97K | +18.9% | $24.03M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | PRIMECAP Management ✦ | 30.86K | -43.6% | $4.44M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Millennium Management ✦ | 9.33K | -92.2% | $1.34M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 6.70K | -78.5% | $964,686 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 5.06K | New | $728,192 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $728,192 | 0.0% |
Exited
| Adage Capital Partners | $14.88M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 436 holders, 65.14M shares, $6.86B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 5.43K sh · $976,680
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology